Jiangsu Nanfang Medical Co., Ltd.
SSE:603880.SS
5.73 (CNY) • At close June 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 602.615 | 600.095 | 545.369 | 527.441 | 1,072.4 | 491.688 | 479.824 | 488.709 | 444.236 | 433.022 | 469.803 | 510.798 | 424.621 |
| Cost of Revenue
| 616.726 | 566.331 | 473.18 | 418.187 | 709.141 | 385.703 | 367.27 | 359.561 | 312.757 | 298.059 | 334.765 | 378.938 | 320.616 |
| Gross Profit
| -14.11 | 33.764 | 72.189 | 109.253 | 363.259 | 105.985 | 112.553 | 129.148 | 131.479 | 134.963 | 135.039 | 131.86 | 104.005 |
| Gross Profit Ratio
| -0.023 | 0.056 | 0.132 | 0.207 | 0.339 | 0.216 | 0.235 | 0.264 | 0.296 | 0.312 | 0.287 | 0.258 | 0.245 |
| Reseach & Development Expenses
| 28.722 | 28.181 | 27.725 | 30.623 | 33.963 | 22.3 | 20.089 | 19.912 | 18.822 | 19.016 | 19.006 | 0 | 0 |
| General & Administrative Expenses
| 50.024 | 18.01 | 15.969 | 29.298 | 18.922 | 11.915 | 16.484 | 10.808 | 16.4 | 19.587 | 17.151 | 48.224 | 41.826 |
| Selling & Marketing Expenses
| 6.998 | 7.728 | 7.19 | 9.163 | 116.452 | 11.877 | 13.667 | 13.194 | 7.897 | 8.646 | 8.536 | 7.84 | 6.572 |
| SG&A
| 57.022 | 25.738 | 23.159 | 38.461 | 135.375 | 23.792 | 30.152 | 24.001 | 24.296 | 28.232 | 25.687 | 56.064 | 48.398 |
| Other Expenses
| 97.851 | 126.666 | 36.429 | 35.695 | 36.103 | 23.034 | -0.758 | -0.044 | 1.338 | 1.108 | 2.07 | 1.524 | -3.635 |
| Operating Expenses
| 183.595 | 180.586 | 87.313 | 104.778 | 205.44 | 69.126 | 73.54 | 69.147 | 66.69 | 67.521 | 59.393 | 58.866 | 50.291 |
| Operating Income
| -197.705 | -146.821 | -0.396 | 6.66 | 163.777 | 44.956 | 45.323 | 49.713 | 60.646 | 60.017 | 60.43 | 55.88 | 46.735 |
| Operating Income Ratio
| -0.328 | -0.245 | -0.001 | 0.013 | 0.153 | 0.091 | 0.094 | 0.102 | 0.137 | 0.139 | 0.129 | 0.109 | 0.11 |
| Total Other Income Expenses Net
| -3.154 | -1.698 | 0.015 | -37.346 | 1.929 | 2.648 | -0.758 | -0.044 | 1.335 | 1.108 | 2.059 | 0.763 | -3.876 |
| Income Before Tax
| -200.859 | -148.519 | -29.344 | -30.686 | 109.886 | 28.05 | 44.565 | 49.669 | 61.792 | 61.125 | 62.489 | 56.643 | 42.86 |
| Income Before Tax Ratio
| -0.333 | -0.247 | -0.054 | -0.058 | 0.102 | 0.057 | 0.093 | 0.102 | 0.139 | 0.141 | 0.133 | 0.111 | 0.101 |
| Income Tax Expense
| -10.363 | -1.23 | -14.407 | -7.648 | 11.602 | 2.9 | 7.759 | 3.244 | 9.755 | 9.654 | 9.18 | 8.598 | 7.093 |
| Net Income
| -190.669 | -147.417 | -14.938 | -23.038 | 98.068 | 28.052 | 39.25 | 47.601 | 51.98 | 51.243 | 53.38 | 48.045 | 35.767 |
| Net Income Ratio
| -0.316 | -0.246 | -0.027 | -0.044 | 0.091 | 0.057 | 0.082 | 0.097 | 0.117 | 0.118 | 0.114 | 0.094 | 0.084 |
| EPS
| -0.66 | -0.51 | -0.052 | -0.079 | 0.34 | 0.098 | 0.14 | 0.2 | 0.24 | 0.24 | 0.25 | 0.22 | 0.17 |
| EPS Diluted
| -0.66 | -0.51 | -0.052 | -0.079 | 0.34 | 0.098 | 0.14 | 0.2 | 0.24 | 0.24 | 0.25 | 0.22 | 0.17 |
| EBITDA
| -123.998 | -76.016 | 28.287 | 12.868 | 132.936 | 49.855 | 64.132 | 69.382 | 79.22 | 76.06 | 80.418 | 79.444 | 53.714 |
| EBITDA Ratio
| -0.206 | -0.127 | 0.052 | 0.024 | 0.124 | 0.101 | 0.134 | 0.142 | 0.178 | 0.176 | 0.171 | 0.156 | 0.126 |